CLSI M02-A11 Antimicrobial Susceptibility Test

EUROLAB, together with its state-of-the-art accredited laboratories and expert team, provides precise and fast testing services within the scope of CLSI M02-A11 testing. This standard includes current Clinical and Laboratory Standards Institute recommended methods for disc susceptibility testing, quality control testing criteria, and updated tables for interpretive zone diameters.

M100-S23 provides updated tables for Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility testing standards M02-A11 and M07-A9.

CLSI's voluntary consensus process relies on contributing authors and/or experts serving as participants in the review and comment process. At the end of each comment period, the committee that developed the document is responsible for reviewing all comments, responding in writing to all significant comments, and revising the draft document as appropriate. All comments and committee responses are kept on file at CLSI and are available upon request.

Susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy if its susceptibility cannot be reliably estimated from the identity of the organism. Susceptibility tests are often indicated when the causative organism is considered to be from a species capable of resistant to commonly used antimicrobial agents.

EUROLAB assists manufacturers with CLSI M02-A11 test compliance. Our test experts, with their professional working mission and principles, provide you, our manufacturers and suppliers, the best service and controlled testing process in our laboratories. Thanks to these services, businesses receive more effective, high-performance and quality testing services and provide safe, fast and uninterrupted service to their customers.